Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24;59(3):2102511.
doi: 10.1183/13993003.02511-2021. Print 2022 Mar.

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

Jeffrey A Tornheim  1 , Zarir F Udwadia  2 , Prerna R Arora  3 , Ishita Gajjar  3 , Nikhil Gupte  1   4 , Samridhi Sharma  3 , Megha Karane  3 , Namrata Sawant  3 , Nisha Kharat  3 , Alexander J Blum  5 , Shri Vijay Bala Yogendra Shivakumar  4 , Jai B Mullerpattan  6 , Lancelot M Pinto  6 , Tester F Ashavaid  3 , Amita Gupta  1   7 , Camilla Rodrigues  8
Affiliations

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

Jeffrey A Tornheim et al. Eur Respir J. .

Abstract

In a longitudinal cohort of MDR-TB patients receiving individualised, DST-based treatment, neither the inclusion of cycloserine in a multidrug regimen nor the dose used (up to 750 mg daily) significantly increased incidence of depression during treatment https://bit.ly/3GtQmOH

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.A. Tornheim reports, during the conduct of the study, salary support from NIH/NIAID (K23AI135102, R21AI122922 and R01AI134430), salary support from the NIH Fogarty International Center (R25TW009340) and salary support from the Johns Hopkins Clinician Scientist Career Development Award; salary support for a study clinician during the first year of the project was provided by the Frederick Mulder Foundation and the Pogge Tong Foundation. C. Rodrigues reports payment for manuscript writing, honoraria for lectures, educational events from Pfizer; honoraria for lectures from Cipla, Glenmark and Novartis; outside the submitted work. All other authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Serial measurement of Patient Health Questionnaire (PHQ)-9 depression scores over the course of treatment for multidrug-resistant tuberculosis. a) Histograms and smoothed regression curves of participants’ PHQ-9 scores among those taking cycloserine during the visit and those not taking cycloserine. b) Smoothed regression curves (lines) and 95% confidence interval ranges (shading) for participants’ PHQ-9 scores, stratified by their daily total dose of cycloserine (mg per day) at each visit. There were no significant differences in PHQ-9 scores by either prescription of cycloserine or cycloserine dose, although participants who did not take cycloserine tended to have higher PHQ-9 scores throughout the course of treatment.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) . WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva, WHO, 2020. - PubMed
    1. Nahid P, Mase SR, Migliori GB, et al. . Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 2019; 200: e93–e142. doi:10.1164/rccm.201909-1874ST - DOI - PMC - PubMed
    1. Hwang TJ, Wares DF, Jafarov A, et al. . Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 2013; 17: 1257–1266. doi:10.5588/ijtld.12.0863 - DOI - PubMed
    1. van der Galiën R, Boveneind-Vrubleuskaya NV, Peloquin C, et al. . Pharmacokinetic modeling, simulation, and development of a limited sampling strategy of cycloserine in patients with multidrug-/extensively drug-resistant tuberculosis. Clin Pharmacokinet 2020; 59: 899–910. doi:10.1007/s40262-020-00860-8 - DOI - PubMed
    1. Zhu M, Nix DE, Adam RD, et al. . Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001; 21: 891–897. doi:10.1592/phco.21.11.891.34524 - DOI - PubMed

Publication types

LinkOut - more resources